ADC Contract Manufacturing Market: Tech Frontiers & Growth Trends

According to Inkwood Research, the global antibody drug conjugates contract manufacturing market is expected to grow at a CAGR of 12.47% over the forecast period 2024 to 2032. Antibody drug conjugate manufacturing is crucial in advancing cancer therapies by combining antibodies and cytotoxic drugs. Companies like Abzena excel in this field, using innovative technologies to overcome traditional challenges. 

Various developments and strategic alliances globally are instrumental in propelling precision medicine forward. Precision medicine revolutionizes healthcare by tailoring treatments based on individual genetic and lifestyle factors. Illumina and Foundation Medicine lead this field, utilizing genomic insights to personalize treatment strategies globally.

Within the Asia-Pacific, particularly in China, these efforts are magnified, with a strong focus on ADC development. This concerted push enhances the region’s influence in drug development and fosters collaborations and innovations.

Antibody_Drug_Conjugates_Contract_Manufacturing_Market_Inkwood_Research

ADC Contract Manufacturing Market: Strategic Alliances in Cancer Therapies

Since the approval of the first ADC in 2000, ADC therapies have become a pivotal advancement in targeted cancer care. Major pharmaceutical players like Novartis and Pfizer, alongside startups, are actively pursuing partnerships within the ADC space to combat cancer effectively.

Numerous domestic companies are now focusing on innovative ADC-based treatments specifically tailored for solid tumors such as breast, gastric, and bladder cancers. This underlines the pharmaceutical industry’s ongoing effort to enhance oncology drugs, with ADCs offering a promising course in targeted cancer treatment.

Concurrently, the year 2023 witnessed a significant surge in ADC-related deals, totaling 76 by December 26th. These deals encompassed a range of activities, such as licensing agreements, collaborations, and acquisitions. 

  • Johnson & Johnson (J&J), for instance, made a significant move on January 8, 2024, with a $2 billion acquisition of ADC developer Ambrx Biopharma, bolstering its ADC pipeline. Prior to this, Johnson & Johnson (J&J) had finalized a significant $1.7 billion agreement with South Korea’s LegoChem Biosciences. The partnership focused on the development and commercialization of LCB84, an exciting Trop2-directed antibody drug conjugate. 
  • Another significant development is AbbVie’s proposed $10 billion acquisition of ImmunoGen. This acquisition includes the flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), an ADC approved for platinum-resistant ovarian cancer (PROC)
  • Eli Lilly, a major American pharmaceutical company, made two notable acquisitions in this field last year. In October 2023, the company acquired French biotech Mablink Bioscience, a pre-clinical biotechnology firm focused on developing next-generation ADCs using its PSARLink proprietary platform. 
  • Further, Daiichi Sankyo and Merck entered into a global partnership for three DXd ADC candidates: HER3-DXd, I-DXd, and R-DXd. This collaboration involves joint development and potential worldwide commercialization, except for Japan, where Daiichi Sankyo retains exclusive rights.

ADC Contract Manufacturing Market | APAC’s Position & Future Outlook 

The Asia-Pacific plays a vital role in ADC development and production, driven by its robust biopharmaceutical industry, research infrastructure, and strategic collaborations. These partnerships foster innovation, accelerate drug discovery, and enhance manufacturing capabilities, leading to advancements in ADC therapies globally.

  • For instance, Singapore’s Hummingbird Bioscience licensed its HER3-ADC, HMBD-501, to Endeavor BioMedicines for up to $430 million in payments. This collaboration signifies the region’s contribution to the antibody drug conjugates contract manufacturing industry. 
  • Likewise, Japanese pharmaceutical giant Takeda secured exclusive global rights from Innate Pharma for ADCs targeting celiac disease. This acquisition showcases the region’s leadership in advancing ADC therapies.

Market Position: According to Inkwood Research, Asia-Pacific is anticipated to be the leading region in the global antibody drug conjugates contract manufacturing market, growing at a CAGR of 13.05% over the forecasted period, 2024 to 2032. 

China has further emerged as a frontrunner in ADC drug development due to partnerships between domestic firms and major global pharmaceutical players. This collaboration-driven approach has propelled China’s prominence in the ADC sector.

Read on to learn more about China’s strategic alliances in ADC drug development

  • Bristol Myers Squibb, in collaboration with SystImmune, entered an exclusive agreement to jointly develop BL-B01D1, an innovative EGFRxHER3 bispecific ADC. 
  • Roche’s billion-dollar licensed agreement with Chinese startup MediLink Therapeutics for YL211 bolsters manufacturing capabilities in the region’s ADC sector.
  • GlaxoSmithKline strengthened its oncology portfolio by acquiring Hansoh Pharma’s gynecologic cancer candidate (HS-20089), demonstrating a commitment to targeted therapies.
  • Eisai and China-based Bliss Biopharmaceutical have teamed up for BlissBio’s ADC candidate targeting Human Epidermal Growth Factor Receptor 2 (HER2).
  • Shanghai-based DualityBio has gained recognition for its advanced ADC technology platform, which led to partnerships with major players such as BioNTech and BeiGene in August 2023

Accordingly, as per Inkwood Research, China is predicted to grow at a CAGR of 12.34% between 2024 to 2032 in the global antibody drug conjugates contract manufacturing market.

Precision in Practice: ADC Contract Manufacturing Industry

ADC production involves precisely conjugating a monoclonal antibody (mAb) with a cytotoxic drug molecule via a linker, creating a targeted therapeutic agent. This process requires expertise in biologics, chemistry, and manufacturing to ensure efficacy and safety while minimizing systemic toxicity. 

Accordingly, Abzena excels as a leading Contract Research Development and Manufacturing Organization (CRDMO), offering a wide range of services from drug discovery to manufacturing. Their competence ensures the meticulous crafting of ADCs with optimal in vivo performance and superior quality attributes. Abzena’s proprietary solutions maximize clinical therapy outcomes. Technologies like AbZelect, AbZelectPRO, ThioBridge, and LabZient enhance precision in interventions.

The success of ADCs hinges on carefully crafting elements like the antibody, linker, and payload. Despite the challenges posed by traditional conjugation methods, such as inconsistent Drug-to-Antibody Ratios (DAR) and linker fragility, advancements are imperative.

Stay up-to-date with what’s trending in the Global Antibody Drug Conjugates Contract Manufacturing Market

Abzena tackles these hurdles with ThioBridge, an advanced conjugation technology. ThioBridge ensures a more consistent DAR profile, preserves ADC integrity and improves stability and effectiveness. Its adaptability and design flexibility streamline ADC manufacturing, leading to cost savings and better results. Hence, these technologies signify a substantial leap forward in ADC production, amplifying enhanced stability, efficacy, and cost-effectiveness, thereby enriching the sphere of targeted therapies.

Increasing global ADC demand is promoting developing growth in the ADC contract manufacturing market. With drug development gaining traction and the Asia-Pacific emerging as a key player, the market is inclined to substantial expansion. Collaborations, technological advancements, and a growing focus on personalized therapies are expected to propel the ADC contract manufacturing market during the forecasting years.

By Harshita Kumari

    Can’t find what you’re looking for? Talk to an expert NOW!

    FAQ

    Regulatory requirements, such as Good Manufacturing Practices (GMP) and guidelines from regulatory bodies like the FDA and EMA, significantly influence ADC contract manufacturing. CMOs must adhere to these standards to ensure product safety, efficacy, consistency, and compliance with regulatory approvals.

    Technology plays a crucial role in ADC contract manufacturing by enabling precise conjugation processes, enhancing product quality and stability, improving manufacturing efficiency, and reducing production costs. Advanced technologies like automation, analytics, and process optimization tools are integral to modern ADC manufacturing facilities.